Nonetheless, we are encouraged that some participants in our study were able to achieve extended clinical benefits with the combination of durvalumab and MEDI0457 beyond what has historically been reported with anti-PD-(L)1 antibodies as monotherapy in patients with advanced HPV-associated cancers. This evidence concerns the gene CD274 and cancer.